Testing effectiveness (Phase 2)Active Not RecruitingNCT05664243
What this trial is testing
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Who this might be right for
Glioblastoma
In8bio Inc. 4